Phathom Pharmaceuticals Inc (NASDAQ:PHAT) price on Thursday, June 12, rose 10.95% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $10.03.
A look at the stock’s price movement, the close in the last trading session was $9.04. Turning to its 52-week performance, $19.71 and $2.21 were the 52-week high and 52-week low respectively. Overall, PHAT moved 203.02% over the past month.
Phathom Pharmaceuticals Inc’s market cap currently stands at around $700.24 million, with investors looking forward to this quarter’s earnings report slated for in July.
Analysts have a consensus estimate of 35.65M for the company’s revenue for the quarter, with a low and high estimate of 32.7M and 37M respectively. The average forecast suggests up to a 386.71% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 159.6M, representing a 188.86% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that PHAT is a 50% Buy. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
10 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 6 recommend PHAT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 2 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
PHAT’s current price about 82.34% and 120.79% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 85.06, while 7-day volatility ratio is 5.09% and 15.18% in the 30-day chart. Further, Phathom Pharmaceuticals Inc (PHAT) has a beta value of 0.15, and an average true range (ATR) of 1.10. Analysts have given the company’s stock an average 52-week price target of $18, forecast between a low of $18 and high of $18. Looking at the price targets, the low is -79.46% off current price level while to achieve the yearly target high, price needs to move -79.46%. Nonetheless, investors will most likely welcome a -79.46% jump to $18 which is the analysts’ median price.
If we refocus on Phathom Pharmaceuticals Inc (NASDAQ:PHAT), historical trading data shows that trading volumes averaged 2.62 million over the past 3 months. The company’s latest data on shares outstanding shows there are 69.64 million shares.
The 45.79% of Phathom Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 47.84% of the company’s shares. Current price change has pushed the stock 23.52% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PHAT stock continues to rise going into the next quarter.
